The August 2003 COM. A 47-year-old woman presented with a long history of muscle pain, weakness, and visual disturbances. Over the last year, she developed diplopia and left sixth nerve palsy. No other neuro-ophthalmologic abnormalities were found. Past medical and family history was unremarkable. Laboratory investigation disclosed hypophosphatemia, phosphaturia, elevated serum alkaline phosphatase activity, and normal serum calcium levels. CT scans showed a lobulated mass arising on the meningeal surface of the cavernous sinus, measuring 3x 2 x 2 cm. The lesion was partially resected and microscopic examination revealed a highly vascularized tumor composed of primitive mesenchymal cells arranged whether in a patternless-pattern or surrounding thin-walled, branching vascular spaces and thick-walled hyalinized vessels. Other eye-catching features were microcystic areas, multinucleated osteoclastic-like giant cells, scattered islands of mature adipocytes, foci of hemorrhage, thrombosed medium-sized-to-large vessels, and hemosiderin-laden macrophages. After surgery, the patient recovered from the muscle pain and weakness, with a significant improvement of serum calcium and alkaline phosphatase levels and phosphate blood levels. Taken together, the clinical and pathologic features were consistent with a diagnosis of phosphaturic mesenchymal tumor (mixed connective tissue variant) of the cavernous sinus in a setting of oncogenic osteomalacia. No further treatment was carried out. The patient has been followed for the last 4 years with no evidence of recurrent disease. Oncogenic osteomalacia is a rare clinical entity characterized by hypophosphatemia, phosphaturia, and a low concentration of 1,25-dihydroxyvitamin D(3) caused by a neoplasm. Pathologists should be aware of this entity, because surgical excision of the tumor is usually curative.
[1]
S. Jan de Beur.
Tumor-induced osteomalacia.
,
2005,
JAMA.
[2]
R. Martuza,et al.
Craniofacial Hemangiopericytoma Associated with Oncogenic Osteomalacia: Case Report
,
2004,
Journal of Neuro-Oncology.
[3]
G. Strewler.
FGF23, hypophosphatemia, and rickets: Has phosphatonin been found?
,
2001,
Proceedings of the National Academy of Sciences of the United States of America.
[4]
S. Takeda,et al.
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
,
2001,
Proceedings of the National Academy of Sciences of the United States of America.
[5]
T. Spector,et al.
The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.
,
2001,
The Journal of clinical endocrinology and metabolism.
[6]
A. Gascón,et al.
Oncogenic osteomalacia in a patient with a fibrocystic nodule of the breast.
,
1999,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7]
N. Weidner.
Review and update: oncogenic osteomalacia-rickets.
,
1991,
Ultrastructural pathology.
[8]
N. Weidner,et al.
Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets
,
1987,
Cancer.
[9]
N. Weidner,et al.
Neoplastic pathology of oncogenic osteomalacia/rickets
,
1985,
Cancer.